HealthEquity (HQY) Earnings Date & Reports

Key Takeaways

• Revenue rose 8% year over year to $350.7 million for the second quarter ended July 31, 2026.
• Net income reached $65.6 million, or $0.78 per diluted share, up from $59.9 million, or $0.68, a year earlier.
• Non-GAAP net income of $1.24 per diluted share exceeded Wall Street's consensus estimate.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 11% to $167.0 million, driving a record 48% margin.
• HealthEquity raised its full-year fiscal 2027 guidance after record HSA (health savings account) assets and stronger-than-expected account growth.

Earnings Context and Why It Matters

HealthEquity (HQY) is the largest independent custodian of health savings accounts (HSAs) by account volume and a leading provider of consumer-directed benefits (CDBs). Its quarterly results are closely watched because they signal both the health of the employer benefits market and the pace at which Americans are accumulating and investing HSA balances. The second quarter of fiscal 2027, ended July 31, 2026, marked the company's second consecutive quarter of accelerating growth, building on momentum from the first quarter. With revenue growth re-accelerating, profitability expanding to record levels, and management lifting its full-year outlook, this report offered investors a clearer read on whether HealthEquity can sustain margin gains while continuing to grow its core HSA franchise.

Reported Results

HealthEquity reported total revenue of $350.7 million for the second quarter ended July 31, 2026, an 8% increase from $325.8 million in the prior-year period. Revenue was driven by $124.4 million in service revenue, $175.9 million in custodial revenue, and $50.4 million in interchange revenue. Total revenue modestly exceeded the consensus estimate of roughly $349.2 million.

Net income was $65.6 million, or $0.78 per diluted share, compared with $59.9 million, or $0.68 per diluted share, a year earlier. Net income margin improved to 19% from 18%. On a non-GAAP basis, which excludes certain non-cash and one-time items, net income was $103.8 million, or $1.24 per diluted share, up from $94.6 million, or $1.08 per diluted share, and above the consensus estimate of approximately $1.15 per share.

Adjusted EBITDA rose 11% to $167.0 million, and the Adjusted EBITDA margin expanded to a company-record 48%, up from 46% in the year-ago quarter. Account metrics were similarly strong: total HSA assets grew 14% to a record $37.9 billion, including $17.4 billion of HSA cash and $20.6 billion of HSA investments. New HSAs from sales increased 24% to 202,000, and total HSAs reached 10.7 million, up 8% year over year.

Management also raised its fiscal 2027 outlook, now expecting revenue of $1.411 billion to $1.421 billion, net income of $242 million to $248 million ($2.88 to $2.96 per diluted share), non-GAAP net income of $392 million to $398 million ($4.66 to $4.73 per diluted share), and Adjusted EBITDA of $628 million to $636 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking earnings season and post-results momentum, the AI Screener offers a structured way to surface relevant opportunities across sectors.

Market Reaction and Investor Sentiment

HealthEquity's second-quarter report was received constructively by investors, with results reflecting the company's strongest non-open-enrollment quarter for new HSA sales on record. The combination of an earnings beat on non-GAAP earnings per share, a record Adjusted EBITDA margin, and a raised full-year guidance supported a favorable interpretation of the quarter. Sentiment was further bolstered by management's disclosure of $108.1 million in share repurchases during the quarter, with approximately $948.4 million remaining under its authorization. The key drivers of investor confidence were accelerating revenue growth, expanding profitability, and sustained account and asset growth, which together suggest the company is converting scale into margin leverage.

Forward Outlook and Key Factors to Monitor

Following this earnings release, investors will be watching whether HealthEquity can maintain its momentum through the second half of fiscal 2027. The company's raised guidance implies continued revenue growth and margin stability, but several factors will determine whether it can deliver on that outlook.

A central variable is the interest-rate environment. A meaningful share of HealthEquity's custodial revenue is tied to the yield earned on HSA cash, so changes in short-term rates could influence future revenue and margins. The company has indicated that a substantial portion of HSA cash remains in contracts repricing during fiscal 2027, making the path of rates an important swing factor.

Account and asset growth also remain key. Investors should monitor new HSA additions from sales, the growth of HSAs with investments, and total HSA assets, which reflect both member acquisition and deeper engagement. Rising participation in invested HSAs tends to support long-term custodial and asset-based revenue.

Finally, capital allocation will be in focus. With a large repurchase authorization in place and ongoing debt paydown, how management balances buybacks against investment in technology and service efficiency will shape per-share results. Cost discipline and operating leverage, evidenced by the record EBITDA margin, will be closely watched in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations